Abstract: The invention relates to methods of identifying therapeutic agents which inhibit triacyglycerol hydrolase (TGH) activity, defined as TGH inhibitors, which are useful in the treatment of conditions resulting from elevated circulating levels of TG, VLDL/LDL-cholesterol and ApoB-100. Also claimed are therapeutic agents which are TGII inhibitors, identifiable by such methods and their use in combating diseases associated with elevated circulating levels of TG, VLDL/LDL-cholesterol and ApoB-100.
Type:
Grant
Filed:
August 24, 2000
Date of Patent:
March 1, 2005
Assignees:
Glaxo Group Limited, The Governors of the University of Alberta
Inventors:
Catherine Sylvia Borg-Capra, Richard Jiri Lehner, Dennis Edward Vance
Abstract: The present invention relates to novel complexes of (transition) metals containing ligands having phosphorus centers supporting a carbene atom or heteroalkane radical bonded to the (transition) metal.
Type:
Grant
Filed:
February 3, 2003
Date of Patent:
February 8, 2005
Assignee:
The Governors of the University of Alberta
Inventors:
Ronald G. Cavell, Ruppa P. Kamalesh Babu, Aparna Kasani
Abstract: The invention disclosed relates to the production of alcohols. A first aspect of the invention relates to a process for production of alcohols, and in particular to a process for the catalytic hydration of an olefin to the corresponding alcohol in substantially anhydrous form, under selected mild reaction conditions, and using a selected catalyst. A second aspect of the invention relates to a process for dehydration of an azeotropic mixture, including a first alcohol and water. A hydration reaction between the water in the azeotropic mixture and an added olefin, under selected mild conditions, and using a selected catalyst, produces a product including a second alcohol corresponding to the olefin, and the first alcohol, in substantially anhydrous form.
Type:
Grant
Filed:
August 1, 2001
Date of Patent:
December 21, 2004
Assignee:
The Governors of the University of Alberta
Abstract: An electrodeposition process for producing a layered composite material and the layered composite material produced by the process. The layered composite material includes at least one layer of a first alloy species of an alloy and at least one layer of a second alloy species of the alloy. The first alloy species and the second alloy species have distinguishable properties. The process includes the steps of first energizing an electroplating circuit to provide a first electroplating current to deposit a layer of the first alloy species and second energizing the electroplating circuit to provide a second electroplating current to deposit a layer of the second alloy species. The alloy is preferably a gold-tin alloy, the first alloy species is preferably the Au5Sn alloy phase and the second alloy species is preferably the AuSn alloy phase.
Type:
Grant
Filed:
December 21, 2001
Date of Patent:
September 28, 2004
Assignee:
The Governors of the University of Alberta
Inventors:
Douglas G. Ivey, Barbara M. Djurfors, Jacobus Cornelius Doesburg
Abstract: This invention relates to a novel microfluidic device and methods of using this device to conduct in vitro studies on the reaction and effects of various compounds on cells. More particularly, it relates to a method for using stop flow in a microfluidic system to study the effect of compounds on individual cells.
Type:
Application
Filed:
August 11, 2003
Publication date:
September 16, 2004
Applicants:
The Governors of the University of Alberta, Alberta Research Council
Inventors:
Daniel Jed Harrison, Paul C.H. Li, Roderick Szarka, Richard Smith, Per Anderson
Abstract: The invention disclosed relates to the production of alcohols. A first aspect of the invention relates to a process for production of alcohols, and in particular to a process for the catalytic hydration of an olefin to the corresponding alcohol in substantially anhydrous form, under selected mild reaction conditions, and using a selected catalyst. A second aspect of the invention relates to a process for dehydration of an azeotropic mixture, including a first alcohol and water. A hydration reaction between the water in the azeotropic mixture and an added olefin, under selected mild conditions, and using a selected catalyst, produces a product including a second alcohol corresponding to the olefin, and the first alcohol, in substantially anhydrous form.
Type:
Application
Filed:
November 13, 2003
Publication date:
August 26, 2004
Applicant:
The Governors of the University of Alberta
Abstract: The present invention is for an apparatus and method for the wireless testing of Integrated Circutis and wafers. The apparatus comprises a test unit external from the wafer and at least one test circuit which is fabricated on the wafer which contains the Integrated Circuit. The test unit transmits an RF signal to power the test circuit. The test circuit, comprising a variable ring oscillator, performs a series of parametric tests at the normal operating frequency of the Integrated Circuit and transmits the test results to the test unit for analysis.
Type:
Application
Filed:
March 1, 2004
Publication date:
August 26, 2004
Applicant:
The Governors of The University of Alberta
Abstract: The present invention provides compositions and methods for maintaining cardiac function by administering dichloroacetate (DCA) in combination with an inotrope.
Abstract: Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have oxygen substitution at C6 and C7, and some have specific stereochemistries such as 6&agr; and 7&bgr; oxygen substitution, and an alpha hydrogen at the 5 position in addition to having 6&agr; and 7&bgr; oxygen substitution. Steroids having 3,4-epoxy functionality are also disclosed. In addition, steroids having C17 pyran and &dgr;-lactone functionality, with oxygen substitution at C6 and C7, or at C15, of the steroid nucleus, are disclosed.
Type:
Application
Filed:
November 6, 2003
Publication date:
August 19, 2004
Applicants:
Inflazyme Pharmaceuticals Ltd., The University of British Columbia, The University of Alberta
Inventors:
David L. Burgoyne, Yaping Shen, John M. Langlands, Christine Rogers, Joseph H.-L. Chau, Edward Piers, Hassan Salari
Abstract: Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have oxygen substitution at C6 and C7, and some have specific stereochemistries such as 6&agr; and 7&bgr; oxygen substitution, and an alpha hydrogen at the 5 position in addition to having 6&agr; and 7&bgr; oxygen substitution. Steroids having 3,4-epoxy functionality are also disclosed. In addition, steroids having C17 pyran and &dgr;-lactone functionality, with oxygen substitution at C6 and C7, or at C15, of the steroid nucleus, are disclosed.
Type:
Application
Filed:
November 6, 2003
Publication date:
August 12, 2004
Applicants:
Inflazyme Pharmaceuticals Ltd., The University of British Columbia, The University of Alberta
Inventors:
David L. Burgoyne, Yaping Shen, John M. Langlands, Christine Rogers, Joseph H.L. Chau, Edward Piers, Hassan Salari
Abstract: A composition and method for treating or preventing infection by Pseudomonas aeruginosa is disclosed. The composition includes a P. aeruginosa pilin peptide modified to prevent oligomerization of the pilin. The method involves administered the composition to a person infected with Pseudomonas are at risk of such infection.
Type:
Grant
Filed:
May 24, 2001
Date of Patent:
July 27, 2004
Assignee:
Governors of the University of Alberta
Inventors:
Randall T. Irvin, Randy J. Read, Bart Hazes, Wah Y. Wong, Sastry A. Parimi, Linda M. G. Glasier
Abstract: A process for recovering fine coals and clarifying water for recycling features with three distinct mechanisms: hydrophobic extraction, electrolyte coagulation, and macromolecular flocculation, which if desired may be integrated into a single stage. The hydrophobic extraction is accomplished using oil to form a coal-in-oil mixture. The process water is clarified using a flocculants, more preferably a combination of coagulant and anionic flocculants. With a well defined reagent addition scheme, this process allows a combustible recovery greater than 88% at an ash content less than 11%, while producing a clean water containing less than 20 ppm suspended solids from a tailing's stream. The coal-in-oil mixture may be used as a fuel for example in coal-firing boilers and power generators.
Type:
Grant
Filed:
January 2, 2002
Date of Patent:
July 27, 2004
Assignee:
Govenors of the University of Alberta
Inventors:
Jaewon Choung, Jozef Szymanski, Zhenghe Xu
Abstract: The present invention is for an apparatus and method for the wireless testing of Integrated Circuits and wafers. The apparatus comprises a test unit external from the wafer and at least one test circuit which is fabricated on the wafer which contains the Integrated Circuit. The test unit transmits an RF signal to power the test circuit. The test circuit, comprising a variable ring oscillator, performs a series of parametric tests at the normal operating frequency of the Integrated Circuit and transmits the test results to the test unit for analysis.
Type:
Grant
Filed:
May 15, 2001
Date of Patent:
July 6, 2004
Assignee:
The Governors of the University of Alberta
Abstract: Functional polymers containing hydroxyl groups as supports for use with catalysts can increase the activity of these catalysts which results in improved ethylene polymerization. The present invention seeks to provide catalysts with improved activity by incorporating 2-hydroxyethyl methacrylate (HEMA) into the support of the catalyst.
Type:
Grant
Filed:
April 30, 2003
Date of Patent:
June 15, 2004
Assignee:
The Governors of the University of Alberta
Inventors:
Peter Phung Minh Hoang, Charles Russell, Jason Roy Kearns, Sieghard E. Wanke, David T. Lynch, Nai-Hong Li
Abstract: A neural prosthesis has a generator of electrical pulses, the pulses having a sine wave shape with frequency greater than 5 kHz, which may be amplitude modulated with a modulator, a blocking electrode for delivery of the electrical pulses to the neuron of the human nerve, the blocking electrode being electrically connected to the generator; and a controller operatively connected to the generator, the controller including an input for receiving control inputs, a control circuit responsive to the control inputs, and an output line responsive to the control circuit for sending output signals, the output signals of the controller including at least a start signal and a stop signal for controlling the generator.
Type:
Application
Filed:
January 13, 2003
Publication date:
May 13, 2004
Applicant:
The Governors of the University of Alberta
Abstract: A method is described relating to the field of cardiovascular disease and in particular the prevention and treatment of poor cardiac function following surgery. An optimum dose of dichloracetate is described, permitting the continuous maintenance of blood therapeutic levels.
Type:
Grant
Filed:
January 18, 2002
Date of Patent:
April 27, 2004
Assignee:
University of Alberta
Inventors:
Gary Lopaschuk, Ruth Collins-Nakai, Koon Teo, Jason R. B. Dyck
Abstract: Human myelin basic protein (h-MBP) has a molecular weight of 18.5 KD and contains 170 amino acid residues. Synthetic peptides ranging in length from about 8 to 25 residues and covering the entire length of the protein have been produced. Antibodies to h-MBP (anti-MBP) were found to be neutralized by the synthetic peptides, in vitro, which span the h-MBP from about amino acid residue 61 to about amino acid residue 106. The peptides, which cover both the amino (about residues 1 to 63) and carboxy (about residues 117 to 162) terminals of h-MBP did not neutralize purified anti-MBP. Intrathecal administratin of peptide MBP(75-95), MBP(86-95), or MBP(82-98) produced complete binding-neutralization of free (F) anti-MBP with no change in bound (B) levels. A control peptide MBP35-58 had no effect on F or B anti-MBP levels. Intravenous administration of MBP(75-95), MBP(86-95), or MBP(82-98) resulted in significant decline of F and B CSF anti-MBP levels.
Type:
Application
Filed:
January 11, 2002
Publication date:
April 15, 2004
Applicant:
The Governors of the University of Alberta
Abstract: Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have oxygen substitution at C6 and C7, and some have specific stereochemistries such as 6&agr; and 7&bgr; oxygen substitution, and an alpha hydrogen at the 5 position in addition to having 6&agr; and 7&bgr; oxygen substitution. Steroids having 3,4-epoxy functionality are also disclosed. In addition, steroids having C17 pyran and &dgr;-lactone functionality, with oxygen substitution at C6 and C7, or at C15, of the steroid nucleus, are disclosed.
Type:
Grant
Filed:
December 23, 1999
Date of Patent:
March 16, 2004
Assignees:
Inflazyme Pharmaceuticals Ltd., University of British Columbia, University of Alberta
Inventors:
David L. Burgoyne, Yaping Shen, John M. Langlands, Christine Rogers, Joseph H.-L. Chau, Edward Piers, Hassan Salari
Abstract: A bacterial &agr;1,2-fucosyltransferase gene and deduced amino acid sequence is provided. The gene is useful for preparing &agr;1,2-fucosyltransferase polypeptide, and active fragment thereof, which can be used in the production of oligosaccharides such as Lewis X, Lewis Y, Lewis B and H type 1, which are structurally similar to certain tumor-associated carbohydrate antigens found in mammals. These product glycoconjugates also have research and diagnostic utility in the development of assays to detect mammalian tumors.
Type:
Application
Filed:
September 15, 2003
Publication date:
March 11, 2004
Applicant:
Governors of the University of Alberta, a Canada corporation